Results 31 to 40 of about 17,377 (218)

Tafamidis Efficacy Among Octogenarian Patients in the Phase 3 ATTR-ACT and Ongoing Long-Term Extension Study. [PDF]

, 2023
Background Tafamidis was approved to treat patients with transthyretin amyloid cardiomyopathy (ATTR-CM) on the basis of findings from the phase 3 Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT).
Witteles, Ronald, Sekijima, Yoshiki, Sultan, Marla B., Perfetto, Federico, García Pavía, Pablo, Gundapaneni, Balarama, Hanna, Mazen, Garcia-Pavia, Pablo, Sultan, Marla B   +8 more
core   +1 more source

Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR‐ACT

, 2021
Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is a progressive, fatal disorder that remains underdiagnosed. The Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) was the first large clinical trial to include both wild‐type (ATTRwt)
Martha Grogan, Balarama Gundapaneni, Gundapaneni, Balarama, Keohane, Denis, Jose Nativi‐Nicolau, Marla B. Sultan, Sultan, Marla B, Judge, Daniel P, Daniel P. Judge, Denis Keohane, Hoffman, James E, Nativi‐Nicolau, Jose, James E. Hoffman, Grogan, Martha   +13 more
core   +1 more source

Breakthrough advances enhancing care in ATTR amyloid cardiomyopathy [PDF]

Transthyretin amyloid cardiomyopathy (ATTR-CM) has been traditionally considered a rare and inexorably fatal condition. ATTR-CM now is an increasingly recognized cause of heart failure (HF) and mortality worldwide with effective pharmacological ...
Porcari, Aldostefano, Sinagra, Gianfranco, Fontana, Marianna, Hawkins, Philip N, Gillmore, Julian D   +4 more
core   +4 more sources

How did transthyretin amyloid cardiomyopathy progress in patients who took placebo in the study ATTR-ACT? A plain language summary

, 2022
What is this plain language summary about? This plain language summary describes some results of a study called ATTR-ACT. This was the first large study to include people with wild-type and hereditary transthyretin amyloid cardiomyopathy (ATTR-CM for ...
Sultan, Marla B, Judge, Daniel P, Gundapaneni, Balarama, Hoffman, James E, Keohane, Denis, Nativi-Nicolau, Jose, Grogan, Martha, Daniel P Judge, Martha Grogan, Balarama Gundapaneni, James E Hoffman, Marla B Sultan, Jose Nativi-Nicolau, Denis Keohane   +13 more
core   +1 more source

Progression of echocardiographic parameters and prognosis in ATTR cardiac amyloidosis [PDF]

, 2022
AIMS: Transthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly diagnosed disease. Echocardiography is widely utilized, but studies to confirm the value of echocardiography for tracking changes over time are not available. We sought to describe: (
Quarta, Candida C, Porcari, Aldostefano, Buonamici, Lodovico, Riefolo, Mattia, Bandera, Francesco, Razvi, Yousuf, Hawkins, Philip N, Potena, Luciano, Gillmore, Julian D, Patel, Rishi, Rowczenio, Dorota, Moon, James, Dal Passo, Beatrice, Whelan, Carol, Chacko, Liza, Moody, William E, Venneri, Lucia, Brown, James, Lachmann, Helen, Petrie, Aviva, Manisty, Charlotte, Wechelakar, Ashutosh, Martinez-Naharro, Ana, Steeds, Richard P, Rapezzi, Claudio, Lazari, Jonathan, Knight, Daniel, Leone, Ornella, Ioannou, Adam, Karia, Nina, Fontana, Marianna, Gilbertson, Janet A   +31 more
core   +1 more source

ATTR amyloidosis during the COVID-19 pandemic: insights from a global medical roundtable

Orphanet Journal of Rare Diseases, 2021
Background The global spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causing the ongoing coronavirus disease 2019 (COVID-19) pandemic has raised serious concern for patients with chronic disease.
Thomas H. Brannagan, Michaela Auer-Grumbach, John L. Berk, Chiara Briani, Vera Bril, Teresa Coelho, Thibaud Damy, Angela Dispenzieri, Brian M. Drachman, Nowell Fine, Hanna K. Gaggin, Morie Gertz, Julian D. Gillmore, Esther Gonzalez, Mazen Hanna, David R. Hurwitz, Sami L. Khella, Mathew S. Maurer, Jose Nativi-Nicolau, Kemi Olugemo, Luis F. Quintana, Andrew M. Rosen, Hartmut H. Schmidt, Jacqueline Shehata, Marcia Waddington-Cruz, Carol Whelan, Frederick L. Ruberg   +26 more
doaj   +1 more source

Cardiac Transthyretin-derived Amyloidosis: An Emerging Target in Heart Failure with Preserved Ejection Fraction?

Cardiac Failure Review, 2020
Heart failure with preserved ejection fraction (HFpEF) comprises half of the heart failure population. A specific, but underdiagnosed, cause for HFpEF is transthyretin-derived (ATTR) amyloidosis.
Sebastiaan HC Klaassen, Dirk J van Veldhuisen, Hans LA Nienhuis, Maarten P van den Berg, Bouke PC Hazenberg, Peter van der Meer   +5 more
doaj   +1 more source

Erythropoietin in Familial Amyloidosis ATTR V30M

, 2013
Familial amyloidosis ATTR V30M is an hereditary disorder, the most frequent type of transthyretin related amyloidosis. The main manifestation of the disease is a sensory-motor and autonomic polyneuropathy.
Costa, P.P., Beirão, I.
core   +1 more source

Prevalence and incidence of amyloid transthyretin amyloidosis in the USA: insights from claims databases and electronic health records

Open Heart
Background Amyloid transthyretin (ATTR) amyloidosis is a rare, life-threatening disease frequently manifesting with cardiomyopathy (ATTR-CM), polyneuropathy (ATTR-PN) or both (ATTR-mixed).
Xiaolei Li, Pedro A Laires, Aishwarya M Uday, Candida Cristina Quarta, Ana Martins Silva   +4 more
doaj   +1 more source

Prevalence of transthyretin amyloidosis among heart failure patients with preserved ejection fraction in Japan

ESC Heart Failure, 2023
Aims Heart failure with preserved ejection fraction (HFpEF), which is caused by wide various conditions, has become a major public health problem. Transthyretin amyloid cardiomyopathy (ATTR‐CM), which is thought to be an underdiagnosed disease, can cause
Takanori Naito, Kazufumi Nakamura, Yukio Abe, Hiroyuki Watanabe, Satoru Sakuragi, Yusuke Katayama, Hajime Kihara, Atsutaka Okizaki, Yusuke Kawai, Masaki Yoshikawa, Atsushi Takaishi, Hideki Fujio, Hiroaki Otsuka, Soichiro Ogura, Hiroshi Ito, ATTR‐HFpEF registry investigators   +15 more
doaj   +1 more source